FDA 483 - Keystone Industries - November 07, 2025

Keystone Industries, a human drug manufacturer in Gibbstown, NJ, was cited for a significant deficiency in drug product component testing. The firm failed to perform required identity testing, including the USP limit test, on incoming high-risk components used in their over-the-counter drug products. This lapse raises concerns about the quality and safety of their manufactured drug products.